<DOC>
	<DOCNO>NCT00174564</DOCNO>
	<brief_summary>The primary objective evaluate efficacy GEMOX treatment 1st line therapy patient advance biliary tract cancer base response rate measure RECIST unidimensional criterion . Secondary objective : Progression free survival , overall survival safety .</brief_summary>
	<brief_title>EXIBIT : Oxaliplatin Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven , locally advanced metastatic carcinoma biliary tract ( gallbladder , intrahepatic bile duct , extrahepatic bile duct , ampula Vater ) For intrahepatic bile duct , diagnosis biliary tract origin evident image surgical exploration , equivalent liver metastasis unknown primary site , inclusion possible : unknown primary exhaustive search primary site ( chest radiography , thoracic abdomino pelvic CT scan , colonoscopy , oesogastroduodenal endoscopy , PSA determination men mammography woman , PET scan possible ) . histological examination compatible adenocarcinoma bile duct immunostaining expression cytokeratin : 7+ , 20 19 + . ( Shimonishi , 2000 ^22 ) No prior chemotherapy advance disease ( first line ) No radiation therapy within 4 week prior first gemcitabine administration . Unidimensionally measurable disease . For female patient childbearing potential , neither pregnant breastfeeding , active contraception No known allergy one study drug No prior malignancy No CNS metastases No peripheral neuropathy &gt; grade 2 ECOG PS &lt; =2 ANC &gt; 1.5 X 10^9 /L Platelets &gt; 100 X 10^9 /L Creatinine &lt; 1.5 x ULN SGPT ( ALT ) &lt; 5 x ULN Bilirubin &lt; 2.5 x ULN ( patient jaundice evidence bile duct obstruction biliary tree decompress endoscopic percutaneous endoprothesis , subsequent reduction bilirubin &lt; 2.5 x ULN eligible study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>